Primary intestinal lymphangiectasia treated with rapamycin in a child with tuberous sclerosis complex (TSC)

Sarah F Pollack1, Alexandra L Geffrey1, Elizabeth A Thiele1

  • 1Department of Neurology, Herscot Center for Tuberous Sclerosis Complex, Massachusetts General Hospital, Boston, Massachusetts.

Insights

Primary intestinal lymphangiectasia, a rare protein-losing enteropathy, was observed in a patient with tuberous sclerosis complex (TSC). Treatment with an mTOR inhibitor, rapamycin, effectively improved symptoms and normalized elevated VEGF-C levels.

Area of Science:

  • Genetics
  • Gastroenterology
  • Oncology

Background:

  • Tuberous sclerosis complex (TSC) is a genetic disorder affecting multiple organs, with known lymphatic system involvement.
  • Primary intestinal lymphangiectasia (PIL) is a rare protein-losing enteropathy due to lymphatic malformations.

Observation:

  • This report details the first case of PIL in a patient with TSC, specifically a female with a TSC2 mutation.
  • The patient presented with severe abdominal distension and chronic diarrhea in infancy.

Findings:

  • Treatment with an mTOR inhibitor, rapamycin, led to significant clinical improvement.
  • Rapamycin normalized elevated VEGF-C levels, a marker associated with lymphatic abnormalities.

Implications:

  • PIL may be a rare manifestation of TSC, expanding the known clinical spectrum of the disorder.
  • mTOR inhibitors show promise for treating this rare combination of conditions, suggesting a therapeutic role in future studies.

Related Concept Videos